Transforming Liver Cancer Treatment with Revolutionary Therapeutic Delivery
A paradigm changing technology enabling controlled tumor drug delivery for superior efficacy
The Challenge: Current therapies do not effectively obliterate the tumor
Liver cancer, the 5th most common global cancer, present a low 5 year survival rate (20%). TACE (Trans Arterial Chemo-Embolization) Therapy has poor results due to:
- Full artery blockage reducing tumor’s drug availability and inducing ischemia.
- The rest of the drug is washed away.
- The single chemo pulse & ischemia are ineffective and may induce tumor growth.
EmboPore provides the solution
Innovative porous microspheres enable optimal blood arterial blockage combined with sustained drug release to improve treatment outcome
EmboPore Solution
A Smarter, More Effective Cancer Therapy
In contrast to current TACE therapy, which completely and immediately blocks blood & chemotherapy flow into the tumor, EmboPore induces partial & optimal blood flow blockage to ensure continuous controlled drug release for up to 14 days.
Innovative porous microspheres embedded with two powerful chemotherapeutic agents Doxorubicin (DOX) & Tirapazamine (TPZ")
Optimized blockage and controlled drug delivery, prolonged tumor treatment
Higher therapeutic efficacy compared to TACE and conventional microspheres
$11 Billion Market – A Unique Investment Opportunity
With over 120,000 patients in the US & EU alone, liver cancer increase rapidly in a 14% CAGR → 360,000 treatments (3 per patient in average)
Orphan drug designation:
- Tax credit on clinical trials
- Fast regulatory track
- 10 yrs market exclusivity (EU) upon approval
- Higher treatment reimbursement
Join the EmboPore Movement
With strong scientific backing, a clear market need, and a patent-pending breakthrough technology, EmboPore is positioned for success. Now is the time to invest.